10 ongoing Clinical Trials on Immunotherapy in Head and Neck cancer

Immunotherapy is transforming the treatment landscape of head and neck cancer—expanding beyond recurrent and metastatic settings into neoadjuvant, adjuvant, and localized delivery strategies. From intratumoral CAR-T cell infusions to intra-arterial checkpoint blockade and PD-1–based chemo-immunotherapy, new trials are redefining how advanced and resectable disease is approached.

Across leading centers in London, Nanjing, New York, and Shanghai, innovative Phase I–III studies are exploring modalities that target the tumor microenvironment, enhance local immune activation, and minimize systemic toxicity. This growing portfolio includes intratumoral T4 CAR-T therapy, intra-arterial immunotherapy, tislelizumab-based induction regimens, and biomarker-driven combinations with radiation, surgery, or targeted agents—all aiming to achieve durable responses in traditionally immunologically “cold” head and neck cancers. Read more here…https://oncodaily.com/oncolibrary/head-and-neck-cancer